All In Biotech

Drug Trial Radar · NCT06904066

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

86

Planned (sponsor's estimate)

Start

Oct 28, 2026

Primary completion

Apr 30, 2029

Study completion Apr 30, 2029

Sponsor

Sponsor type
NIH
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes. Researchers want to test a method of treating blood cancers by altering a person s T cells (a type of immune cell) to target neoepitopes. Objective: To test the use of neoepitope-specific T cells in people with blood cancers Eligibility: People aged 18 with any of 9 blood cancers. Design: Participants will have a bone marrow biopsy: A sample of soft tissue will be removed from inside a pelvic bone. This is needed to confirm their diagnosis and the TP53 and RAS mutations in their cancer cells. They will also have a skin biopsy to look for these mutations in other tissue. Participants will undergo apheresis: Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The T cells will be grown to become neoepitope-specific T cells. Participants receive drugs for 3 days to prepare their body for the treatment. The modified T cells will be given through a tube inserted into a vein. Participants will need to remain in the clinic at least 7 days after treatment. Participants will have 8 follow-up visits in the first year after treatment. They will have 6 more visits over the next 4 years. Long-term follow-up will go on for 10 more years.

Conditions

  • Malignancy, Hematologic
  • Neoplasms, Hematologic
  • Neoplasms, Hematopoietic
  • Blood Cancer
  • Hematological Neoplasms
  • Hematopoietic Malignancies
  • Dysmyelopoietic Syndromes
  • Hematopoetic Myelodysplasia
  • Myeloid Leukemia, Acute
  • Nonlymphoblastic Leukemia, Acute
  • Leukemia, Lymphocytic, Acute

Interventions

  • aldesleukinDrug

    Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).

  • cyclophosphamideDrug

    300 mg/m\^2 IV infusion over 30 minutes. Daily x 3 doses on days -5, -4, -3.

  • fludarabine phosphateDrug

    30 mg/m\^2 IV infusion over 30 minutes administered immediately following cyclophosphamide on day -5, -4, -3. Participants with renal dysfunction receive a lower dose of fludarabine.

  • Individual Patient TCR-Transduced PBLBiological

    Up to 1.5x10\^11 total cells for non-transplant subjects. 1x10\^10 total cells for post-alloHSCT subjects.

  • TruSight Oncology (TSO) 500Device

    TSO500 sequencing panel performed in the NCI Laboratory of Pathology to detect TP53 or RAS mutations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: From time of the lymphodepleting chemotherapy through 5 years after neoepitope-specific T cell infusion or until off study.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.